Cirrhosis and its complications

肝硬化及其并发症

• 批准号: 7030300
• 负责人: GUADALUPE GARCIA-TSAO
• 金额: $ 15.42万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-01 至 2010-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7030300
• 关键词: albumins; ascites; blood pressure; clinical research; hemorrhage; hospital utilization; human subject; human therapy evaluation; liver cirrhosis; liver disorder chemotherapy; liver failure; liver transplantation; medical complication; octreotide; patient oriented research; peritonitis; thoracic surgery; vasoconstrictors

DESCRIPTION (provided by applicant): Dr. Garcia-Tsao is Professor of Medicine at Yale University School of Medicine. She has dedicated her professional life to the study of complications of cirrhosis through patient-oriented research. Since having been awarded the K-24 award she has continued to significantly contribute to the knowledge of cirrhosis, a significant cause of mortality in the productive years of life. The project proposed in the initial K-24 submission was successfully completed and resulted in a publication that has led to the recommendation of using large-volume paracentesis + albumin as standard of care in the treatment of refractory ascites. As a rational followup to this study, Dr. Garcia-Tsao has now received funding to evaluate the effect of a combination of vasoconstrictors ooctreotide+midodrine) as alternative to albumin after large-volume paracentesis. Another of the goals outlined in her original K-24 submission was to focus on prophylactic therapy and on the identification of prognostic factors in chronic liver disease. In this regard, Dr. Garcia-Tsao has importantly contributed to the completion of a long trial of beta-blocker in the prevention of varices and identified portal pressure as an important predictor of cirrhosis decompensation not only in all cirrhotic patients, but particularly in those with cirrhosis secondary to hepatitis C. As program director of one of four VA Hepatitis C Resource Centers (granted during the term of the K-24 award) she will apply this knowledge to studies of antiviral therapy in the prevention of cirrhosis decompensation. As Director of the recently funded Clinical Core of the Yale Liver Center she will continue to devote major efforts toward mentoring beginning clinical investigators in POR. Mentoring of junior faculty, postgraduate fellows, medical students in POR has almost doubled since obtaining the K-24 award. Renewal of the award will allow Dr. Garcia-Tsao to maintain both POR and her mentoring endeavors to their fullest extent so she can continue to make significant contributions in the field of chronic liver disease and its complications.

描述（由申请人提供）：Garcia-Tsao博士是耶鲁大学医学院医学教授。她通过以患者为导向的研究致力于研究肝硬化并发症的研究。自获得K-24奖以来，她继续为肝硬化的知识做出重大贡献，这是生产力的生命年份死亡率的重要原因。最初的K-24提交中提出的项目已成功完成，并导致出版物导致建议使用大容量的超肠溶剂 +白蛋白作为治疗难治性腹水的护理标准。作为这项研究的合理随访，Garcia-Tsao博士现已获得资金，以评估血管收缩剂 - 卵巢肽+Midodrine的效果）作为大量超肠术后白蛋白的替代品。她最初的K-24提交中概述的另一个目标是专注于预防性治疗以及鉴定慢性肝病的预后因素。 In this regard, Dr. Garcia-Tsao has importantly contributed to the completion of a long trial of beta-blocker in the prevention of varices and identified portal pressure as an important predictor of cirrhosis decompensation not only in all cirrhotic patients, but particularly in those with cirrhosis secondary to hepatitis C. As program director of one of four VA Hepatitis C Resource Centers (granted during the term of the K-24 award)她将把这些知识应用于抗病毒疗法的研究，以预防肝硬化代偿失调。作为最近资助的耶鲁肝脏中心临床核心的主任，她将继续致力于指导POR的临床研究人员。自获得K-24奖以来，POR的医学生的初级教职员工，研究生研究员，POR的医学生几乎翻了一番。该奖项的续签将使Garcia-tsao博士能够最大程度地维持POR和她的指导努力，以便她可以继续在慢性肝病及其并发症领域做出重大贡献。